The presentation and publication of the BRUIN CLL-314 trial followed the FDA’s December 3 decision to expand approval for ...

Bruton’s tyrosine kinase inhibitors such as ibrutinib have significantly improved outcomes for chronic lymphocytic leukemia, ...

The aim of the fixed-duration approach is to "produce deep remissions and thereby allow patients to get off therapy while ...

Eli Lilly's fast-growing blood cancer drug Jaypirca has bagged a new FDA approval as an earlier treatment for relapsed or ...

Eli Lilly and Company has received approval from the US FDA for the expanded use of Jaypirca tablets in 100mg and 50mg doses.

Pirtobrutinib significantly improved PFS in previously untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma compared with a standard chemoimmunotherapy regimen in a ...

The U.S. Food and Drug Administration (FDA) has granted traditional approval to Jaypirca (pirobrutinib) for the treatment of ...

Eli Lilly receives US FDA expanded indication approval for Jaypirca to treat adults with relapsed or refractory chronic lymphocytic leukaemia: Indianapolis Saturday, December 6, 2 ...

Indianapolis: Eli Lilly and Company has announced that the U.S. Food and Drug Administration (FDA) has granted approval to ...

Eli Lilly and Co. (LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Jaypirca (pirtobrutinib, 100 mg and 50 mg tablets) for the treatment of ...

The treatment regimen achieved a 100% overall response rate, with 95% of patients reaching complete response after brexucabtagene autoleucel infusion. Safety concerns included cytokine release ...

AstraZeneca advances its ambition to redefine hematology care with new data from its diverse pipeline and portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, ...